Equities researchers at StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a research note issued to investors on Friday. The brokerage set a "sell" rating on the biotechnology company's stock.
Several other equities analysts also recently issued reports on GNCA. Stifel Nicolaus downgraded shares of Genocea Biosciences from a "buy" rating to a "hold" rating in a research note on Friday, April 29th. HC Wainwright downgraded shares of Genocea Biosciences from a "buy" rating to a "neutral" rating in a research note on Friday, April 29th. Finally, Robert W. Baird lowered their target price on shares of Genocea Biosciences from $8.00 to $3.00 in a research note on Monday, April 11th.
Get
Genocea Biosciences alerts:
Shares of NASDAQ:GNCA opened at $0.01 on Friday. The company has a market cap of $828,149.40, a price-to-earnings ratio of -0.02 and a beta of 2.26. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35. The firm has a 50 day simple moving average of $0.10 and a 200 day simple moving average of $0.69. Genocea Biosciences has a one year low of $0.01 and a one year high of $2.24.
In other news, Director Ali Behbahani sold 4,445,093 shares of the business's stock in a transaction that occurred on Wednesday, May 25th. The shares were sold at an average price of $0.08, for a total value of $355,607.44. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Paul Edward Walker sold 5,931,843 shares of the business's stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $0.07, for a total transaction of $415,229.01. Following the transaction, the insider now directly owns 4,445,093 shares of the company's stock, valued at approximately $311,156.51. The disclosure for this sale can be found here. Insiders have sold 10,537,612 shares of company stock worth $781,461 over the last three months. 1.61% of the stock is owned by insiders.
A hedge fund recently raised its stake in Genocea Biosciences stock. Commonwealth Equity Services LLC boosted its position in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 31,981 shares of the biotechnology company's stock after buying an additional 10,576 shares during the quarter. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 as of its most recent filing with the Securities & Exchange Commission. 59.25% of the stock is owned by hedge funds and other institutional investors.
About Genocea Biosciences (Get Rating)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Further Reading
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Credo Technology Stock is Rebounding
- Investing In Preferred Stock vs. Common Stock
- Profiting From 52 Week Low Stocks
- Three Cheap Stocks The Insiders Are Buying
- Is Roblox A Good Play For The 2nd Half
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
